US21217B1008
US21217B1008
Contineum Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 68.059.000 | 50.894.000 | 33.7% | |
| Operating Income | -68.059.000 | -50.894.000 | 33.7% |
| Pretax Income | -59.978.000 | -42.258.000 | 41.9% |
| Net Income Common Stockholders | -59.978.000 | -42.258.000 | 41.9% |
| -- | -- | -- | |
| -- | -- | -- |